{"result": "(\"entity\"<|>TRASPLANTE HEPÁTICO<|>EVENT<|>Liver transplantation is a therapeutic option for patients with classic MSUD and other metabolic disorders, aimed at correcting metabolic defects.)\n##\n(\"entity\"<|>NUEVAS TÉCNICAS QUIRÚRGICAS<|>EVENT<|>New surgical techniques have been developed in recent decades to improve outcomes for liver transplant patients.)\n##\n(\"entity\"<|>INMUNOSUPRESIÓN<|>EVENT<|>Immunosuppression is a necessary treatment following liver transplantation to prevent organ rejection.)\n##\n(\"entity\"<|>HOMOCISTINA<|>PERSON<|>Homocystine is an amino acid that accumulates in the body due to metabolic disorders like homocystinuria.)\n##\n(\"entity\"<|>CISTEÍNA<|>PERSON<|>Cysteine is an amino acid that is decreased in the body due to metabolic disorders such as homocystinuria.)\n##\n(\"entity\"<|>TAURINA<|>PERSON<|>Taurine is an amino acid that may also be affected in metabolic disorders like homocystinuria.)\n##\n(\"relationship\"<|>TRASPLANTE HEPÁTICO<|>MSUD<|>Liver transplantation is a potential treatment for patients with Maple Syrup Urine Disease, addressing the underlying metabolic issues<|>8)\n##\n(\"relationship\"<|>TRASPLANTE HEPÁTICO<|>HOMOCISTINURIA<|>Liver transplantation may also be considered for patients with homocystinuria to correct metabolic defects<|>8)\n##\n(\"relationship\"<|>NUEVAS TÉCNICAS QUIRÚRGICAS<|>TRASPLANTE HEPÁTICO<|>New surgical techniques have improved the success rates of liver transplants<|>7)\n##\n(\"relationship\"<|>INMUNOSUPRESIÓN<|>TRASPLANTE HEPÁTICO<|>Immunosuppression is a critical part of post-operative care following liver transplantation<|>9)\n##\n(\"relationship\"<|>HOMOCISTINA<|>HOMOCISTINURIA<|>Homocystine levels are elevated in individuals with homocystinuria, leading to various health complications<|>9)\n##\n(\"relationship\"<|>CISTEÍNA<|>HOMOCISTINURIA<|>Cysteine levels are decreased in patients with homocystinuria, affecting their overall metabolism<|>8)\n##\n(\"relationship\"<|>TAURINA<|>HOMOCISTINURIA<|>Taurine levels may also be impacted in individuals with homocystinuria, contributing to metabolic imbalances<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: jable en el postoperatorio mantener 24-48\n  Patata                   7%               5%             6%     horas más estas medidas y reintroducir aporte proteico\n                                                                  pasadas estas horas.\n  Pastas, pan              8%               4%             5%\n  Mantequilla              8%               6%             7%     3.6.   Nuevas terapias\n  Frutas                  4-5%              3%            3-4%      El trasplante hepático es una opción terapéutica para\n                                                                  los pacientes con MSUD clásica que tienen una insigni-\n\n\n\n                 Tabla 6.    Polímeros de glucosa.\n\n\n\n                       Edad (años)                Concentración  Calorías /100 ml              Volumen/día\n                             0-1                        10%               40                  150-200 ml/kg\n                             1-2                        15%               60                      95 ml/kg\n                             2-6                        20%               80                1200-1500 ml/día\n                            6-10                        20%               80                1500-2000 ml/día\n                            >10                         25%               100                   2000 ml/día\n\n---\n                                                  Tema 18.      Soporte nutricional en metabolopatías de los aminoácidos…                  313\n\n\n\nficante actividad residual enzimática. Cabe destacar, sin                    4.   Homocistinuria\nembargo, que no el 100% de la actividad enzimática se\nexpresa en el hígado, por lo que el trasplante hepático                      4.1.    Consideraciones generales\ncorrige parcialmente el defecto metabólico.                                     La homocistinuria es una enfermedad autosómica\n   A pesar de las complicaciones que esta opción lleva                       recesiva del metabolismo de la metionina (Met), pre-\nconsigo (cirugía muy compleja, inmunosupresión, re-                          sente en uno de cada 200.000-335.000 nacidos vivos\nchazo), en las últimas décadas se han desarrollado                           (más frecuente en Irlanda), producida en su forma\nnuevas técnicas quirúrgicas y nuevos regímenes inmu-                         clásica por una deficiencia de cistationina β            sintetasa\nnosupresores. Con todo ello, se han conseguido mejo-                         aunque, en casos raros, la origina una deficiencia de\nres resultados tanto a nivel metabólico como de cali-                        5-metiltetrahidrofolato-homocisteína metiltransferasa,\ndad de vida en estos pacientes.                                              metionina sintetasa, su cofactor metilcobalamina o de\n   Los datos de la literatura apoyan los beneficios a lar-                   5,10-metilentetrahidrofolato reductasa, siendo esta úl-\ngo plazo del trasplante19.                                                   tima la causa más frecuente de hiperhomocistinemia\n   Recientemente se está postulando el empleo de fe-                         moderada (figura 3) 21; también puede estar ocasiona-\nnilbutirato como opción terapéutica en la MSUD, ya                           da de forma muy infrecuente por una alteración en el\nque es capaz de inhibir enzimas quinasas y regular el                        transporte intracelular de cobalamina, manifestándose\ncomplejo deshidrogenasa BCAA, consiguiendo dismi-                            solo con homocistinuria, con aciduria metilmalónica o\nnuir los niveles séricos de los mismos.                                      ambas. El resultado de cualquiera de las posibles cau-\n   No obstante, hacen falta más estudios para confir-                        sas es un acúmulo de homocisteína, homocistina y me-\nmar el beneficio de dicho fármaco en la MSUD a largo                         tionina y una disminución de cisteína y taurina en el\nplazo20.                                                                     organismo.\n                                                                       Met                                   DimetilGly\n                          THF\n                                                     Adenosina             S-adenosil metil\n                                                                           transferasa\n                                                                 S-adenosilMet\n                                                        R-H\n                                 HomoCys metil                             Metil\n                                 transferasa                               transferasa\n                                                         R-CH3\n                                   Cobalamina                 S-adenosilhomoCys\n                                                        HO2                Adenosil\n                                                                           homocisteinasa\n                                                  Adenosina\n                       5-metilTHF                                  HomoCys                                       Betaína\n                                                     Serina                Cistationina\n                                                         Piridoxina        β-sintetasa\n\n\n\n                                                                  Cistationina\n                                                                                                           α-cetobutirato\n                                                     Cistationinasa                  Homoserina\n                                    Glutatión                          Cys                        Cistina\n\n\n\n                                                                     Taurina\n\n\n\n                 Figura 3.    Metabolismo de la metionina. Cys: cisteína; Gly: glicina; Met: metionina;\n                 R: radical; THF: tetrahidrofolato. En az\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HOSPITAL TRANSPLANTE<|>ORGANIZATION<|>The hospital specializing in liver transplants for patients with metabolic disorders, particularly those with classic MSUD.)\n##\n(\"entity\"<|>MSUD<|>EVENT<|>Maple Syrup Urine Disease (MSUD) is a metabolic disorder that requires specialized nutritional support and may necessitate a liver transplant.)\n##\n(\"entity\"<|>HOMOCISTINURIA<|>EVENT<|>Homocystinuria is an autosomal recessive disorder of methionine metabolism, which can lead to serious health complications.)\n##\n(\"entity\"<|>IRELAND<|>GEO<|>Ireland is noted for having a higher prevalence of homocystinuria, occurring in one of every 200,000-335,000 live births.)\n##\n(\"entity\"<|>CISTATIONINA β-SINTETASA<|>PERSON<|>Cystathionine β-synthase is an enzyme whose deficiency is a common cause of homocystinuria.)\n##\n(\"entity\"<|>5-METILTETRAHIDROFOLATO-HOMOCISTEÍNA METILTRANSFERASA<|>PERSON<|>5-methyltetrahydrofolate-homocysteine methyltransferase is an enzyme involved in the metabolism of homocysteine, and its deficiency can lead to hyperhomocystinemia.)\n##\n(\"entity\"<|>METIONINA SINTETASA<|>PERSON<|>Methionine synthase is an enzyme that plays a role in the metabolism of methionine and can be involved in conditions like homocystinuria.)\n##\n(\"entity\"<|>METILCOBALAMINA<|>PERSON<|>Methylcobalamin is a cofactor for methionine synthase and is essential for proper metabolism of homocysteine.)\n##\n(\"entity\"<|>5,10-METILENTETRAHIDROFOLATO REDUCTASA<|>PERSON<|>5,10-methylenetetrahydrofolate reductase is an enzyme that can cause hyperhomocystinemia when deficient.)\n##\n(\"relationship\"<|>HOSPITAL TRANSPLANTE<|>MSUD<|>The hospital provides treatment options for patients suffering from Maple Syrup Urine Disease, including liver transplants<|>8)\n##\n(\"relationship\"<|>HOSPITAL TRANSPLANTE<|>HOMOCISTINURIA<|>The hospital also addresses cases of homocystinuria, providing necessary medical interventions<|>8)\n##\n(\"relationship\"<|>HOMOCISTINURIA<|>IRELAND<|>Ireland has a noted prevalence of homocystinuria, making it a significant location for studies and treatments related to this condition<|>6)\n##\n(\"relationship\"<|>CISTATIONINA β-SINTETASA<|>HOMOCISTINURIA<|>Cystathionine β-synthase deficiency is a common cause of homocystinuria<|>9)\n##\n(\"relationship\"<|>5-METILTETRAHIDROFOLATO-HOMOCISTEÍNA METILTRANSFERASA<|>HOMOCISTINURIA<|>Deficiency of this enzyme can lead to hyperhomocystinemia, which is related to homocystinuria<|>9)\n##\n(\"relationship\"<|>METIONINA SINTETASA<|>HOMOCISTINURIA<|>Methionine synthase deficiency can also contribute to the development of homocystinuria<|>9)\n##\n(\"relationship\"<|>METILCOBALAMINA<|>HOMOCISTINURIA<|>Methylcobalamin is essential for the function of methionine synthase, which is involved in the metabolism of homocysteine<|>8)\n##\n(\"relationship\"<|>5,10-METILENTETRAHIDROFOLATO REDUCTASA<|>HOMOCISTINURIA<|>Deficiency in this enzyme can lead to elevated homocysteine levels, contributing to homocystinuria<|>9)\n<|COMPLETE|>"}]}